nodes	percent_of_prediction	percent_of_DWPC	metapath
Lamivudine—Gemcitabine—urinary bladder cancer	0.418	1	CrCtD
Lamivudine—Zalcitabine—Gemcitabine—urinary bladder cancer	0.114	0.522	CrCrCtD
Lamivudine—CMPK1—Gemcitabine—urinary bladder cancer	0.0935	0.376	CbGbCtD
Lamivudine—Cytarabine—Gemcitabine—urinary bladder cancer	0.0547	0.251	CrCrCtD
Lamivudine—Decitabine—Gemcitabine—urinary bladder cancer	0.0495	0.227	CrCrCtD
Lamivudine—DCK—Gemcitabine—urinary bladder cancer	0.0239	0.0961	CbGbCtD
Lamivudine—ABCC3—Fluorouracil—urinary bladder cancer	0.0106	0.0426	CbGbCtD
Lamivudine—ABCC3—Cisplatin—urinary bladder cancer	0.00901	0.0362	CbGbCtD
Lamivudine—ABCC3—Etoposide—urinary bladder cancer	0.00885	0.0356	CbGbCtD
Lamivudine—ABCC4—Fluorouracil—urinary bladder cancer	0.0081	0.0326	CbGbCtD
Lamivudine—ABCC1—Epirubicin—urinary bladder cancer	0.00697	0.028	CbGbCtD
Lamivudine—ABCB1—Mitomycin—urinary bladder cancer	0.00638	0.0256	CbGbCtD
Lamivudine—ABCC3—Doxorubicin—urinary bladder cancer	0.00603	0.0243	CbGbCtD
Lamivudine—ABCC3—Methotrexate—urinary bladder cancer	0.00585	0.0235	CbGbCtD
Lamivudine—ABCC1—Etoposide—urinary bladder cancer	0.00543	0.0218	CbGbCtD
Lamivudine—SLC22A2—Cisplatin—urinary bladder cancer	0.00501	0.0201	CbGbCtD
Lamivudine—ABCC2—Carboplatin—urinary bladder cancer	0.00479	0.0193	CbGbCtD
Lamivudine—ABCC4—Methotrexate—urinary bladder cancer	0.00447	0.018	CbGbCtD
Lamivudine—ABCG2—Fluorouracil—urinary bladder cancer	0.00436	0.0175	CbGbCtD
Lamivudine—ABCG2—Carboplatin—urinary bladder cancer	0.00433	0.0174	CbGbCtD
Lamivudine—ABCC2—Cisplatin—urinary bladder cancer	0.00409	0.0164	CbGbCtD
Lamivudine—ABCC2—Etoposide—urinary bladder cancer	0.00402	0.0162	CbGbCtD
Lamivudine—ABCC1—Doxorubicin—urinary bladder cancer	0.00371	0.0149	CbGbCtD
Lamivudine—ABCG2—Cisplatin—urinary bladder cancer	0.0037	0.0149	CbGbCtD
Lamivudine—ABCG2—Etoposide—urinary bladder cancer	0.00364	0.0146	CbGbCtD
Lamivudine—ABCC1—Methotrexate—urinary bladder cancer	0.00359	0.0144	CbGbCtD
Lamivudine—ABCC2—Doxorubicin—urinary bladder cancer	0.00274	0.011	CbGbCtD
Lamivudine—ABCC2—Methotrexate—urinary bladder cancer	0.00266	0.0107	CbGbCtD
Lamivudine—ABCG2—Doxorubicin—urinary bladder cancer	0.00248	0.00997	CbGbCtD
Lamivudine—ABCG2—Methotrexate—urinary bladder cancer	0.0024	0.00965	CbGbCtD
Lamivudine—SLC22A6—Methotrexate—urinary bladder cancer	0.00194	0.00781	CbGbCtD
Lamivudine—ABCB1—Gemcitabine—urinary bladder cancer	0.00184	0.00738	CbGbCtD
Lamivudine—ABCB1—Cisplatin—urinary bladder cancer	0.00133	0.00536	CbGbCtD
Lamivudine—NT5C—prostate gland—urinary bladder cancer	0.00132	0.0487	CbGeAlD
Lamivudine—ABCB1—Etoposide—urinary bladder cancer	0.00131	0.00527	CbGbCtD
Lamivudine—PCYT2—renal system—urinary bladder cancer	0.00124	0.0457	CbGeAlD
Lamivudine—Cytarabine—POLB—urinary bladder cancer	0.00101	0.538	CrCbGaD
Lamivudine—PCYT2—female reproductive system—urinary bladder cancer	0.000991	0.0366	CbGeAlD
Lamivudine—NT5C—renal system—urinary bladder cancer	0.000898	0.0332	CbGeAlD
Lamivudine—ABCB1—Doxorubicin—urinary bladder cancer	0.000894	0.00359	CbGbCtD
Lamivudine—NT5C—urethra—urinary bladder cancer	0.000882	0.0326	CbGeAlD
Lamivudine—ABCB1—Methotrexate—urinary bladder cancer	0.000866	0.00348	CbGbCtD
Lamivudine—PGK1—female reproductive system—urinary bladder cancer	0.000851	0.0315	CbGeAlD
Lamivudine—PCYT1A—renal system—urinary bladder cancer	0.000842	0.0311	CbGeAlD
Lamivudine—NME1—prostate gland—urinary bladder cancer	0.000826	0.0305	CbGeAlD
Lamivudine—CMPK1—prostate gland—urinary bladder cancer	0.000796	0.0294	CbGeAlD
Lamivudine—NME2—prostate gland—urinary bladder cancer	0.000778	0.0288	CbGeAlD
Lamivudine—NME1-NME2—female reproductive system—urinary bladder cancer	0.000775	0.0287	CbGeAlD
Lamivudine—NT5C—female reproductive system—urinary bladder cancer	0.000719	0.0266	CbGeAlD
Lamivudine—PCYT1A—female reproductive system—urinary bladder cancer	0.000675	0.0249	CbGeAlD
Lamivudine—NT5C—vagina—urinary bladder cancer	0.00065	0.024	CbGeAlD
Lamivudine—Gemcitabine—RRM2—urinary bladder cancer	0.000591	0.314	CrCbGaD
Lamivudine—NME2—epithelium—urinary bladder cancer	0.000572	0.0211	CbGeAlD
Lamivudine—CMPK1—smooth muscle tissue—urinary bladder cancer	0.000564	0.0208	CbGeAlD
Lamivudine—NME1—renal system—urinary bladder cancer	0.000563	0.0208	CbGeAlD
Lamivudine—CMPK1—renal system—urinary bladder cancer	0.000543	0.0201	CbGeAlD
Lamivudine—NME2—renal system—urinary bladder cancer	0.00053	0.0196	CbGeAlD
Lamivudine—NME1-NME2—lymph node—urinary bladder cancer	0.000454	0.0168	CbGeAlD
Lamivudine—NME1—female reproductive system—urinary bladder cancer	0.000451	0.0167	CbGeAlD
Lamivudine—CMPK1—female reproductive system—urinary bladder cancer	0.000435	0.0161	CbGeAlD
Lamivudine—NME2—female reproductive system—urinary bladder cancer	0.000425	0.0157	CbGeAlD
Lamivudine—NT5C—lymph node—urinary bladder cancer	0.000421	0.0155	CbGeAlD
Lamivudine—DCK—prostate gland—urinary bladder cancer	0.000397	0.0147	CbGeAlD
Lamivudine—CMPK1—vagina—urinary bladder cancer	0.000393	0.0145	CbGeAlD
Lamivudine—ABCC3—prostate gland—urinary bladder cancer	0.00038	0.014	CbGeAlD
Lamivudine—DCK—Epirubicin—Valrubicin—urinary bladder cancer	0.000352	0.374	CbGdCrCtD
Lamivudine—DCK—Doxorubicin—Valrubicin—urinary bladder cancer	0.000352	0.374	CbGdCrCtD
Lamivudine—DCK—seminal vesicle—urinary bladder cancer	0.000335	0.0124	CbGeAlD
Lamivudine—SLC22A2—renal system—urinary bladder cancer	0.000326	0.0121	CbGeAlD
Lamivudine—SLC22A3—prostate gland—urinary bladder cancer	0.000323	0.0119	CbGeAlD
Lamivudine—ABCC4—prostate gland—urinary bladder cancer	0.000313	0.0116	CbGeAlD
Lamivudine—ABCC2—prostate gland—urinary bladder cancer	0.000303	0.0112	CbGeAlD
Lamivudine—Gemcitabine—TYMS—urinary bladder cancer	0.000278	0.148	CrCbGaD
Lamivudine—SLC22A3—seminal vesicle—urinary bladder cancer	0.000273	0.0101	CbGeAlD
Lamivudine—ABCC1—prostate gland—urinary bladder cancer	0.000267	0.00988	CbGeAlD
Lamivudine—DCK—urethra—urinary bladder cancer	0.000265	0.00981	CbGeAlD
Lamivudine—NME1—lymph node—urinary bladder cancer	0.000264	0.00975	CbGeAlD
Lamivudine—ABCC3—renal system—urinary bladder cancer	0.000259	0.00956	CbGeAlD
Lamivudine—CMPK1—lymph node—urinary bladder cancer	0.000254	0.0094	CbGeAlD
Lamivudine—NME2—lymph node—urinary bladder cancer	0.000249	0.00919	CbGeAlD
Lamivudine—SLC22A1—renal system—urinary bladder cancer	0.00023	0.00852	CbGeAlD
Lamivudine—SLC22A3—smooth muscle tissue—urinary bladder cancer	0.000229	0.00846	CbGeAlD
Lamivudine—ABCC1—seminal vesicle—urinary bladder cancer	0.000226	0.00835	CbGeAlD
Lamivudine—ABCG2—prostate gland—urinary bladder cancer	0.000221	0.00818	CbGeAlD
Lamivudine—SLC22A3—renal system—urinary bladder cancer	0.00022	0.00814	CbGeAlD
Lamivudine—DCK—female reproductive system—urinary bladder cancer	0.000216	0.008	CbGeAlD
Lamivudine—SLC22A3—urethra—urinary bladder cancer	0.000216	0.008	CbGeAlD
Lamivudine—ABCC4—renal system—urinary bladder cancer	0.000214	0.00789	CbGeAlD
Lamivudine—ABCC3—female reproductive system—urinary bladder cancer	0.000207	0.00766	CbGeAlD
Lamivudine—ABCC2—renal system—urinary bladder cancer	0.000207	0.00764	CbGeAlD
Lamivudine—DCK—vagina—urinary bladder cancer	0.000196	0.00723	CbGeAlD
Lamivudine—ABCG2—seminal vesicle—urinary bladder cancer	0.000187	0.00691	CbGeAlD
Lamivudine—ABCC1—urethra—urinary bladder cancer	0.000179	0.00661	CbGeAlD
Lamivudine—SLC22A3—female reproductive system—urinary bladder cancer	0.000176	0.00652	CbGeAlD
Lamivudine—ABCC4—female reproductive system—urinary bladder cancer	0.000171	0.00632	CbGeAlD
Lamivudine—SLC22A1—vagina—urinary bladder cancer	0.000167	0.00617	CbGeAlD
Lamivudine—ABCC2—female reproductive system—urinary bladder cancer	0.000166	0.00612	CbGeAlD
Lamivudine—SLC22A3—vagina—urinary bladder cancer	0.00016	0.0059	CbGeAlD
Lamivudine—ABCG2—urethra—urinary bladder cancer	0.000148	0.00547	CbGeAlD
Lamivudine—ABCC1—vagina—urinary bladder cancer	0.000132	0.00488	CbGeAlD
Lamivudine—DCK—lymph node—urinary bladder cancer	0.000127	0.00468	CbGeAlD
Lamivudine—DCK—Doxorubicin—Epirubicin—urinary bladder cancer	0.000122	0.13	CbGdCrCtD
Lamivudine—ABCC3—lymph node—urinary bladder cancer	0.000121	0.00448	CbGeAlD
Lamivudine—DCK—Epirubicin—Doxorubicin—urinary bladder cancer	0.000113	0.121	CbGdCrCtD
Lamivudine—ABCG2—vagina—urinary bladder cancer	0.000109	0.00404	CbGeAlD
Lamivudine—ABCB1—prostate gland—urinary bladder cancer	0.000109	0.00403	CbGeAlD
Lamivudine—SLC22A3—lymph node—urinary bladder cancer	0.000103	0.00381	CbGeAlD
Lamivudine—ABCC4—lymph node—urinary bladder cancer	0.0001	0.0037	CbGeAlD
Lamivudine—ABCC2—lymph node—urinary bladder cancer	9.69e-05	0.00358	CbGeAlD
Lamivudine—ABCB1—seminal vesicle—urinary bladder cancer	9.23e-05	0.00341	CbGeAlD
Lamivudine—ABCC1—lymph node—urinary bladder cancer	8.53e-05	0.00315	CbGeAlD
Lamivudine—ABCB1—epithelium—urinary bladder cancer	8.02e-05	0.00296	CbGeAlD
Lamivudine—ABCB1—renal system—urinary bladder cancer	7.43e-05	0.00275	CbGeAlD
Lamivudine—ABCB1—urethra—urinary bladder cancer	7.3e-05	0.0027	CbGeAlD
Lamivudine—ABCG2—lymph node—urinary bladder cancer	7.06e-05	0.00261	CbGeAlD
Lamivudine—ABCB1—female reproductive system—urinary bladder cancer	5.95e-05	0.0022	CbGeAlD
Lamivudine—ABCB1—vagina—urinary bladder cancer	5.39e-05	0.00199	CbGeAlD
Lamivudine—ABCB1—lymph node—urinary bladder cancer	3.48e-05	0.00129	CbGeAlD
Lamivudine—Hepatobiliary disease—Epirubicin—urinary bladder cancer	3.13e-05	0.000721	CcSEcCtD
Lamivudine—Epistaxis—Epirubicin—urinary bladder cancer	3.12e-05	0.000719	CcSEcCtD
Lamivudine—Pruritus—Gemcitabine—urinary bladder cancer	3.12e-05	0.000718	CcSEcCtD
Lamivudine—Nausea—Thiotepa—urinary bladder cancer	3.11e-05	0.000717	CcSEcCtD
Lamivudine—Sinusitis—Epirubicin—urinary bladder cancer	3.1e-05	0.000715	CcSEcCtD
Lamivudine—Feeling abnormal—Etoposide—urinary bladder cancer	3.1e-05	0.000715	CcSEcCtD
Lamivudine—Hyperglycaemia—Doxorubicin—urinary bladder cancer	3.1e-05	0.000713	CcSEcCtD
Lamivudine—Agranulocytosis—Epirubicin—urinary bladder cancer	3.09e-05	0.000711	CcSEcCtD
Lamivudine—Gastrointestinal pain—Etoposide—urinary bladder cancer	3.08e-05	0.000709	CcSEcCtD
Lamivudine—Pruritus—Fluorouracil—urinary bladder cancer	3.07e-05	0.000706	CcSEcCtD
Lamivudine—Stevens-Johnson syndrome—Doxorubicin—urinary bladder cancer	3.03e-05	0.000699	CcSEcCtD
Lamivudine—Hypersensitivity—Cisplatin—urinary bladder cancer	3.03e-05	0.000697	CcSEcCtD
Lamivudine—Diarrhoea—Gemcitabine—urinary bladder cancer	3.02e-05	0.000695	CcSEcCtD
Lamivudine—Renal failure—Doxorubicin—urinary bladder cancer	3.01e-05	0.000693	CcSEcCtD
Lamivudine—Erythema multiforme—Methotrexate—urinary bladder cancer	3e-05	0.000691	CcSEcCtD
Lamivudine—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	3e-05	0.000691	CcSEcCtD
Lamivudine—Urticaria—Etoposide—urinary bladder cancer	2.99e-05	0.000689	CcSEcCtD
Lamivudine—Jaundice—Doxorubicin—urinary bladder cancer	2.98e-05	0.000687	CcSEcCtD
Lamivudine—Stomatitis—Doxorubicin—urinary bladder cancer	2.98e-05	0.000687	CcSEcCtD
Lamivudine—Rhinitis—Epirubicin—urinary bladder cancer	2.98e-05	0.000686	CcSEcCtD
Lamivudine—Abdominal pain—Etoposide—urinary bladder cancer	2.98e-05	0.000685	CcSEcCtD
Lamivudine—Body temperature increased—Etoposide—urinary bladder cancer	2.98e-05	0.000685	CcSEcCtD
Lamivudine—Hepatitis—Epirubicin—urinary bladder cancer	2.97e-05	0.000684	CcSEcCtD
Lamivudine—Diarrhoea—Fluorouracil—urinary bladder cancer	2.97e-05	0.000683	CcSEcCtD
Lamivudine—Hypoaesthesia—Epirubicin—urinary bladder cancer	2.95e-05	0.000681	CcSEcCtD
Lamivudine—Asthenia—Cisplatin—urinary bladder cancer	2.95e-05	0.000679	CcSEcCtD
Lamivudine—Pharyngitis—Epirubicin—urinary bladder cancer	2.95e-05	0.000679	CcSEcCtD
Lamivudine—Sweating—Doxorubicin—urinary bladder cancer	2.93e-05	0.000676	CcSEcCtD
Lamivudine—Connective tissue disorder—Epirubicin—urinary bladder cancer	2.92e-05	0.000672	CcSEcCtD
Lamivudine—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	2.89e-05	0.000667	CcSEcCtD
Lamivudine—Epistaxis—Doxorubicin—urinary bladder cancer	2.89e-05	0.000665	CcSEcCtD
Lamivudine—Sinusitis—Doxorubicin—urinary bladder cancer	2.87e-05	0.000662	CcSEcCtD
Lamivudine—Immune system disorder—Methotrexate—urinary bladder cancer	2.87e-05	0.00066	CcSEcCtD
Lamivudine—Dizziness—Fluorouracil—urinary bladder cancer	2.87e-05	0.00066	CcSEcCtD
Lamivudine—Mediastinal disorder—Methotrexate—urinary bladder cancer	2.86e-05	0.000659	CcSEcCtD
Lamivudine—Agranulocytosis—Doxorubicin—urinary bladder cancer	2.86e-05	0.000658	CcSEcCtD
Lamivudine—Chills—Methotrexate—urinary bladder cancer	2.85e-05	0.000656	CcSEcCtD
Lamivudine—Diarrhoea—Cisplatin—urinary bladder cancer	2.81e-05	0.000648	CcSEcCtD
Lamivudine—Erythema multiforme—Epirubicin—urinary bladder cancer	2.81e-05	0.000647	CcSEcCtD
Lamivudine—Alopecia—Methotrexate—urinary bladder cancer	2.8e-05	0.000646	CcSEcCtD
Lamivudine—Vomiting—Gemcitabine—urinary bladder cancer	2.8e-05	0.000646	CcSEcCtD
Lamivudine—Rash—Gemcitabine—urinary bladder cancer	2.78e-05	0.00064	CcSEcCtD
Lamivudine—Dermatitis—Gemcitabine—urinary bladder cancer	2.78e-05	0.00064	CcSEcCtD
Lamivudine—Hypersensitivity—Etoposide—urinary bladder cancer	2.77e-05	0.000639	CcSEcCtD
Lamivudine—Erythema—Methotrexate—urinary bladder cancer	2.76e-05	0.000636	CcSEcCtD
Lamivudine—Malnutrition—Methotrexate—urinary bladder cancer	2.76e-05	0.000636	CcSEcCtD
Lamivudine—Headache—Gemcitabine—urinary bladder cancer	2.76e-05	0.000636	CcSEcCtD
Lamivudine—Vomiting—Fluorouracil—urinary bladder cancer	2.76e-05	0.000635	CcSEcCtD
Lamivudine—Rhinitis—Doxorubicin—urinary bladder cancer	2.75e-05	0.000635	CcSEcCtD
Lamivudine—Hepatitis—Doxorubicin—urinary bladder cancer	2.75e-05	0.000633	CcSEcCtD
Lamivudine—Hypoaesthesia—Doxorubicin—urinary bladder cancer	2.73e-05	0.00063	CcSEcCtD
Lamivudine—Rash—Fluorouracil—urinary bladder cancer	2.73e-05	0.00063	CcSEcCtD
Lamivudine—Dermatitis—Fluorouracil—urinary bladder cancer	2.73e-05	0.000629	CcSEcCtD
Lamivudine—Pharyngitis—Doxorubicin—urinary bladder cancer	2.73e-05	0.000628	CcSEcCtD
Lamivudine—Headache—Fluorouracil—urinary bladder cancer	2.71e-05	0.000625	CcSEcCtD
Lamivudine—Dysgeusia—Methotrexate—urinary bladder cancer	2.7e-05	0.000623	CcSEcCtD
Lamivudine—Asthenia—Etoposide—urinary bladder cancer	2.7e-05	0.000622	CcSEcCtD
Lamivudine—Connective tissue disorder—Doxorubicin—urinary bladder cancer	2.7e-05	0.000622	CcSEcCtD
Lamivudine—Immune system disorder—Epirubicin—urinary bladder cancer	2.68e-05	0.000618	CcSEcCtD
Lamivudine—Mediastinal disorder—Epirubicin—urinary bladder cancer	2.68e-05	0.000617	CcSEcCtD
Lamivudine—Back pain—Methotrexate—urinary bladder cancer	2.67e-05	0.000616	CcSEcCtD
Lamivudine—Chills—Epirubicin—urinary bladder cancer	2.66e-05	0.000614	CcSEcCtD
Lamivudine—Pruritus—Etoposide—urinary bladder cancer	2.66e-05	0.000613	CcSEcCtD
Lamivudine—Alopecia—Epirubicin—urinary bladder cancer	2.62e-05	0.000605	CcSEcCtD
Lamivudine—Nausea—Gemcitabine—urinary bladder cancer	2.62e-05	0.000603	CcSEcCtD
Lamivudine—Vomiting—Cisplatin—urinary bladder cancer	2.61e-05	0.000602	CcSEcCtD
Lamivudine—Erythema multiforme—Doxorubicin—urinary bladder cancer	2.6e-05	0.000599	CcSEcCtD
Lamivudine—Rash—Cisplatin—urinary bladder cancer	2.59e-05	0.000597	CcSEcCtD
Lamivudine—Dermatitis—Cisplatin—urinary bladder cancer	2.59e-05	0.000596	CcSEcCtD
Lamivudine—Malnutrition—Epirubicin—urinary bladder cancer	2.58e-05	0.000596	CcSEcCtD
Lamivudine—Erythema—Epirubicin—urinary bladder cancer	2.58e-05	0.000596	CcSEcCtD
Lamivudine—Diarrhoea—Etoposide—urinary bladder cancer	2.58e-05	0.000593	CcSEcCtD
Lamivudine—Nausea—Fluorouracil—urinary bladder cancer	2.57e-05	0.000593	CcSEcCtD
Lamivudine—Ill-defined disorder—Methotrexate—urinary bladder cancer	2.56e-05	0.00059	CcSEcCtD
Lamivudine—Anaemia—Methotrexate—urinary bladder cancer	2.55e-05	0.000588	CcSEcCtD
Lamivudine—Flatulence—Epirubicin—urinary bladder cancer	2.55e-05	0.000587	CcSEcCtD
Lamivudine—Tension—Epirubicin—urinary bladder cancer	2.54e-05	0.000584	CcSEcCtD
Lamivudine—Dysgeusia—Epirubicin—urinary bladder cancer	2.53e-05	0.000583	CcSEcCtD
Lamivudine—Nervousness—Epirubicin—urinary bladder cancer	2.51e-05	0.000578	CcSEcCtD
Lamivudine—Back pain—Epirubicin—urinary bladder cancer	2.5e-05	0.000576	CcSEcCtD
Lamivudine—Malaise—Methotrexate—urinary bladder cancer	2.49e-05	0.000574	CcSEcCtD
Lamivudine—Dizziness—Etoposide—urinary bladder cancer	2.49e-05	0.000573	CcSEcCtD
Lamivudine—Muscle spasms—Epirubicin—urinary bladder cancer	2.49e-05	0.000573	CcSEcCtD
Lamivudine—Immune system disorder—Doxorubicin—urinary bladder cancer	2.48e-05	0.000572	CcSEcCtD
Lamivudine—Vertigo—Methotrexate—urinary bladder cancer	2.48e-05	0.000572	CcSEcCtD
Lamivudine—Mediastinal disorder—Doxorubicin—urinary bladder cancer	2.48e-05	0.000571	CcSEcCtD
Lamivudine—Leukopenia—Methotrexate—urinary bladder cancer	2.47e-05	0.00057	CcSEcCtD
Lamivudine—Chills—Doxorubicin—urinary bladder cancer	2.47e-05	0.000568	CcSEcCtD
Lamivudine—Nausea—Cisplatin—urinary bladder cancer	2.44e-05	0.000562	CcSEcCtD
Lamivudine—Alopecia—Doxorubicin—urinary bladder cancer	2.43e-05	0.000559	CcSEcCtD
Lamivudine—Cough—Methotrexate—urinary bladder cancer	2.41e-05	0.000555	CcSEcCtD
Lamivudine—Ill-defined disorder—Epirubicin—urinary bladder cancer	2.4e-05	0.000553	CcSEcCtD
Lamivudine—Convulsion—Methotrexate—urinary bladder cancer	2.39e-05	0.000551	CcSEcCtD
Lamivudine—Vomiting—Etoposide—urinary bladder cancer	2.39e-05	0.000551	CcSEcCtD
Lamivudine—Malnutrition—Doxorubicin—urinary bladder cancer	2.39e-05	0.000551	CcSEcCtD
Lamivudine—Erythema—Doxorubicin—urinary bladder cancer	2.39e-05	0.000551	CcSEcCtD
Lamivudine—Anaemia—Epirubicin—urinary bladder cancer	2.39e-05	0.00055	CcSEcCtD
Lamivudine—Rash—Etoposide—urinary bladder cancer	2.37e-05	0.000547	CcSEcCtD
Lamivudine—Dermatitis—Etoposide—urinary bladder cancer	2.37e-05	0.000546	CcSEcCtD
Lamivudine—Headache—Etoposide—urinary bladder cancer	2.36e-05	0.000543	CcSEcCtD
Lamivudine—Flatulence—Doxorubicin—urinary bladder cancer	2.36e-05	0.000543	CcSEcCtD
Lamivudine—Chest pain—Methotrexate—urinary bladder cancer	2.35e-05	0.000542	CcSEcCtD
Lamivudine—Myalgia—Methotrexate—urinary bladder cancer	2.35e-05	0.000542	CcSEcCtD
Lamivudine—Arthralgia—Methotrexate—urinary bladder cancer	2.35e-05	0.000542	CcSEcCtD
Lamivudine—Tension—Doxorubicin—urinary bladder cancer	2.35e-05	0.000541	CcSEcCtD
Lamivudine—Dysgeusia—Doxorubicin—urinary bladder cancer	2.34e-05	0.00054	CcSEcCtD
Lamivudine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	2.34e-05	0.000538	CcSEcCtD
Lamivudine—Malaise—Epirubicin—urinary bladder cancer	2.33e-05	0.000537	CcSEcCtD
Lamivudine—Discomfort—Methotrexate—urinary bladder cancer	2.32e-05	0.000535	CcSEcCtD
Lamivudine—Nervousness—Doxorubicin—urinary bladder cancer	2.32e-05	0.000535	CcSEcCtD
Lamivudine—Vertigo—Epirubicin—urinary bladder cancer	2.32e-05	0.000535	CcSEcCtD
Lamivudine—Syncope—Epirubicin—urinary bladder cancer	2.32e-05	0.000534	CcSEcCtD
Lamivudine—Leukopenia—Epirubicin—urinary bladder cancer	2.31e-05	0.000533	CcSEcCtD
Lamivudine—Back pain—Doxorubicin—urinary bladder cancer	2.31e-05	0.000533	CcSEcCtD
Lamivudine—Muscle spasms—Doxorubicin—urinary bladder cancer	2.3e-05	0.00053	CcSEcCtD
Lamivudine—Confusional state—Methotrexate—urinary bladder cancer	2.27e-05	0.000524	CcSEcCtD
Lamivudine—Loss of consciousness—Epirubicin—urinary bladder cancer	2.27e-05	0.000523	CcSEcCtD
Lamivudine—Cough—Epirubicin—urinary bladder cancer	2.26e-05	0.00052	CcSEcCtD
Lamivudine—Anaphylactic shock—Methotrexate—urinary bladder cancer	2.25e-05	0.000519	CcSEcCtD
Lamivudine—Convulsion—Epirubicin—urinary bladder cancer	2.24e-05	0.000516	CcSEcCtD
Lamivudine—Infection—Methotrexate—urinary bladder cancer	2.24e-05	0.000516	CcSEcCtD
Lamivudine—Nausea—Etoposide—urinary bladder cancer	2.24e-05	0.000515	CcSEcCtD
Lamivudine—Ill-defined disorder—Doxorubicin—urinary bladder cancer	2.22e-05	0.000511	CcSEcCtD
Lamivudine—Nervous system disorder—Methotrexate—urinary bladder cancer	2.21e-05	0.000509	CcSEcCtD
Lamivudine—Anaemia—Doxorubicin—urinary bladder cancer	2.21e-05	0.000509	CcSEcCtD
Lamivudine—Thrombocytopenia—Methotrexate—urinary bladder cancer	2.21e-05	0.000509	CcSEcCtD
Lamivudine—Arthralgia—Epirubicin—urinary bladder cancer	2.2e-05	0.000507	CcSEcCtD
Lamivudine—Chest pain—Epirubicin—urinary bladder cancer	2.2e-05	0.000507	CcSEcCtD
Lamivudine—Myalgia—Epirubicin—urinary bladder cancer	2.2e-05	0.000507	CcSEcCtD
Lamivudine—Anxiety—Epirubicin—urinary bladder cancer	2.19e-05	0.000505	CcSEcCtD
Lamivudine—Skin disorder—Methotrexate—urinary bladder cancer	2.19e-05	0.000504	CcSEcCtD
Lamivudine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	2.19e-05	0.000504	CcSEcCtD
Lamivudine—Hyperhidrosis—Methotrexate—urinary bladder cancer	2.18e-05	0.000502	CcSEcCtD
Lamivudine—Discomfort—Epirubicin—urinary bladder cancer	2.17e-05	0.000501	CcSEcCtD
Lamivudine—Malaise—Doxorubicin—urinary bladder cancer	2.16e-05	0.000497	CcSEcCtD
Lamivudine—Dry mouth—Epirubicin—urinary bladder cancer	2.15e-05	0.000496	CcSEcCtD
Lamivudine—Vertigo—Doxorubicin—urinary bladder cancer	2.15e-05	0.000495	CcSEcCtD
Lamivudine—Anorexia—Methotrexate—urinary bladder cancer	2.15e-05	0.000495	CcSEcCtD
Lamivudine—Syncope—Doxorubicin—urinary bladder cancer	2.14e-05	0.000494	CcSEcCtD
Lamivudine—Leukopenia—Doxorubicin—urinary bladder cancer	2.14e-05	0.000493	CcSEcCtD
Lamivudine—Confusional state—Epirubicin—urinary bladder cancer	2.13e-05	0.00049	CcSEcCtD
Lamivudine—Anaphylactic shock—Epirubicin—urinary bladder cancer	2.11e-05	0.000486	CcSEcCtD
Lamivudine—Oedema—Epirubicin—urinary bladder cancer	2.11e-05	0.000486	CcSEcCtD
Lamivudine—Hypotension—Methotrexate—urinary bladder cancer	2.11e-05	0.000485	CcSEcCtD
Lamivudine—Loss of consciousness—Doxorubicin—urinary bladder cancer	2.1e-05	0.000484	CcSEcCtD
Lamivudine—Infection—Epirubicin—urinary bladder cancer	2.1e-05	0.000483	CcSEcCtD
Lamivudine—Cough—Doxorubicin—urinary bladder cancer	2.09e-05	0.000481	CcSEcCtD
Lamivudine—Shock—Epirubicin—urinary bladder cancer	2.08e-05	0.000478	CcSEcCtD
Lamivudine—Convulsion—Doxorubicin—urinary bladder cancer	2.07e-05	0.000477	CcSEcCtD
Lamivudine—Nervous system disorder—Epirubicin—urinary bladder cancer	2.07e-05	0.000477	CcSEcCtD
Lamivudine—Thrombocytopenia—Epirubicin—urinary bladder cancer	2.07e-05	0.000476	CcSEcCtD
Lamivudine—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	2.05e-05	0.000473	CcSEcCtD
Lamivudine—Skin disorder—Epirubicin—urinary bladder cancer	2.05e-05	0.000472	CcSEcCtD
Lamivudine—Hyperhidrosis—Epirubicin—urinary bladder cancer	2.04e-05	0.00047	CcSEcCtD
Lamivudine—Insomnia—Methotrexate—urinary bladder cancer	2.04e-05	0.00047	CcSEcCtD
Lamivudine—Myalgia—Doxorubicin—urinary bladder cancer	2.04e-05	0.000469	CcSEcCtD
Lamivudine—Arthralgia—Doxorubicin—urinary bladder cancer	2.04e-05	0.000469	CcSEcCtD
Lamivudine—Chest pain—Doxorubicin—urinary bladder cancer	2.04e-05	0.000469	CcSEcCtD
Lamivudine—Anxiety—Doxorubicin—urinary bladder cancer	2.03e-05	0.000468	CcSEcCtD
Lamivudine—Paraesthesia—Methotrexate—urinary bladder cancer	2.02e-05	0.000466	CcSEcCtD
Lamivudine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	2.02e-05	0.000466	CcSEcCtD
Lamivudine—Discomfort—Doxorubicin—urinary bladder cancer	2.01e-05	0.000464	CcSEcCtD
Lamivudine—Anorexia—Epirubicin—urinary bladder cancer	2.01e-05	0.000463	CcSEcCtD
Lamivudine—Dyspnoea—Methotrexate—urinary bladder cancer	2.01e-05	0.000463	CcSEcCtD
Lamivudine—Somnolence—Methotrexate—urinary bladder cancer	2e-05	0.000462	CcSEcCtD
Lamivudine—Dry mouth—Doxorubicin—urinary bladder cancer	1.99e-05	0.000459	CcSEcCtD
Lamivudine—Dyspepsia—Methotrexate—urinary bladder cancer	1.98e-05	0.000457	CcSEcCtD
Lamivudine—Hypotension—Epirubicin—urinary bladder cancer	1.97e-05	0.000454	CcSEcCtD
Lamivudine—Confusional state—Doxorubicin—urinary bladder cancer	1.97e-05	0.000453	CcSEcCtD
Lamivudine—Decreased appetite—Methotrexate—urinary bladder cancer	1.96e-05	0.000452	CcSEcCtD
Lamivudine—Oedema—Doxorubicin—urinary bladder cancer	1.95e-05	0.00045	CcSEcCtD
Lamivudine—Anaphylactic shock—Doxorubicin—urinary bladder cancer	1.95e-05	0.00045	CcSEcCtD
Lamivudine—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	1.95e-05	0.000448	CcSEcCtD
Lamivudine—Fatigue—Methotrexate—urinary bladder cancer	1.94e-05	0.000448	CcSEcCtD
Lamivudine—Infection—Doxorubicin—urinary bladder cancer	1.94e-05	0.000447	CcSEcCtD
Lamivudine—Pain—Methotrexate—urinary bladder cancer	1.93e-05	0.000444	CcSEcCtD
Lamivudine—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	1.92e-05	0.000443	CcSEcCtD
Lamivudine—Shock—Doxorubicin—urinary bladder cancer	1.92e-05	0.000442	CcSEcCtD
Lamivudine—Nervous system disorder—Doxorubicin—urinary bladder cancer	1.91e-05	0.000441	CcSEcCtD
Lamivudine—Thrombocytopenia—Doxorubicin—urinary bladder cancer	1.91e-05	0.00044	CcSEcCtD
Lamivudine—Insomnia—Epirubicin—urinary bladder cancer	1.91e-05	0.00044	CcSEcCtD
Lamivudine—Skin disorder—Doxorubicin—urinary bladder cancer	1.9e-05	0.000437	CcSEcCtD
Lamivudine—Paraesthesia—Epirubicin—urinary bladder cancer	1.89e-05	0.000436	CcSEcCtD
Lamivudine—Hyperhidrosis—Doxorubicin—urinary bladder cancer	1.89e-05	0.000435	CcSEcCtD
Lamivudine—Dyspnoea—Epirubicin—urinary bladder cancer	1.88e-05	0.000433	CcSEcCtD
Lamivudine—Somnolence—Epirubicin—urinary bladder cancer	1.88e-05	0.000432	CcSEcCtD
Lamivudine—Anorexia—Doxorubicin—urinary bladder cancer	1.86e-05	0.000429	CcSEcCtD
Lamivudine—Feeling abnormal—Methotrexate—urinary bladder cancer	1.86e-05	0.000428	CcSEcCtD
Lamivudine—Dyspepsia—Epirubicin—urinary bladder cancer	1.86e-05	0.000428	CcSEcCtD
Lamivudine—Gastrointestinal pain—Methotrexate—urinary bladder cancer	1.84e-05	0.000425	CcSEcCtD
Lamivudine—Decreased appetite—Epirubicin—urinary bladder cancer	1.83e-05	0.000423	CcSEcCtD
Lamivudine—Hypotension—Doxorubicin—urinary bladder cancer	1.82e-05	0.00042	CcSEcCtD
Lamivudine—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	1.82e-05	0.00042	CcSEcCtD
Lamivudine—Fatigue—Epirubicin—urinary bladder cancer	1.82e-05	0.000419	CcSEcCtD
Lamivudine—Constipation—Epirubicin—urinary bladder cancer	1.8e-05	0.000416	CcSEcCtD
Lamivudine—Pain—Epirubicin—urinary bladder cancer	1.8e-05	0.000416	CcSEcCtD
Lamivudine—Urticaria—Methotrexate—urinary bladder cancer	1.79e-05	0.000413	CcSEcCtD
Lamivudine—Abdominal pain—Methotrexate—urinary bladder cancer	1.78e-05	0.000411	CcSEcCtD
Lamivudine—Body temperature increased—Methotrexate—urinary bladder cancer	1.78e-05	0.000411	CcSEcCtD
Lamivudine—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	1.78e-05	0.00041	CcSEcCtD
Lamivudine—Insomnia—Doxorubicin—urinary bladder cancer	1.77e-05	0.000407	CcSEcCtD
Lamivudine—Paraesthesia—Doxorubicin—urinary bladder cancer	1.75e-05	0.000404	CcSEcCtD
Lamivudine—Dyspnoea—Doxorubicin—urinary bladder cancer	1.74e-05	0.000401	CcSEcCtD
Lamivudine—Feeling abnormal—Epirubicin—urinary bladder cancer	1.74e-05	0.000401	CcSEcCtD
Lamivudine—Somnolence—Doxorubicin—urinary bladder cancer	1.74e-05	0.0004	CcSEcCtD
Lamivudine—Gastrointestinal pain—Epirubicin—urinary bladder cancer	1.73e-05	0.000397	CcSEcCtD
Lamivudine—Dyspepsia—Doxorubicin—urinary bladder cancer	1.72e-05	0.000396	CcSEcCtD
Lamivudine—Decreased appetite—Doxorubicin—urinary bladder cancer	1.7e-05	0.000391	CcSEcCtD
Lamivudine—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	1.69e-05	0.000388	CcSEcCtD
Lamivudine—Fatigue—Doxorubicin—urinary bladder cancer	1.68e-05	0.000388	CcSEcCtD
Lamivudine—Urticaria—Epirubicin—urinary bladder cancer	1.68e-05	0.000386	CcSEcCtD
Lamivudine—Constipation—Doxorubicin—urinary bladder cancer	1.67e-05	0.000385	CcSEcCtD
Lamivudine—Pain—Doxorubicin—urinary bladder cancer	1.67e-05	0.000385	CcSEcCtD
Lamivudine—Abdominal pain—Epirubicin—urinary bladder cancer	1.67e-05	0.000384	CcSEcCtD
Lamivudine—Body temperature increased—Epirubicin—urinary bladder cancer	1.67e-05	0.000384	CcSEcCtD
Lamivudine—Hypersensitivity—Methotrexate—urinary bladder cancer	1.66e-05	0.000383	CcSEcCtD
Lamivudine—Asthenia—Methotrexate—urinary bladder cancer	1.62e-05	0.000373	CcSEcCtD
Lamivudine—Feeling abnormal—Doxorubicin—urinary bladder cancer	1.61e-05	0.000371	CcSEcCtD
Lamivudine—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	1.6e-05	0.000368	CcSEcCtD
Lamivudine—Pruritus—Methotrexate—urinary bladder cancer	1.59e-05	0.000367	CcSEcCtD
Lamivudine—Hypersensitivity—Epirubicin—urinary bladder cancer	1.55e-05	0.000358	CcSEcCtD
Lamivudine—Urticaria—Doxorubicin—urinary bladder cancer	1.55e-05	0.000357	CcSEcCtD
Lamivudine—Abdominal pain—Doxorubicin—urinary bladder cancer	1.54e-05	0.000356	CcSEcCtD
Lamivudine—Body temperature increased—Doxorubicin—urinary bladder cancer	1.54e-05	0.000356	CcSEcCtD
Lamivudine—Diarrhoea—Methotrexate—urinary bladder cancer	1.54e-05	0.000355	CcSEcCtD
Lamivudine—Asthenia—Epirubicin—urinary bladder cancer	1.51e-05	0.000349	CcSEcCtD
Lamivudine—Pruritus—Epirubicin—urinary bladder cancer	1.49e-05	0.000344	CcSEcCtD
Lamivudine—Dizziness—Methotrexate—urinary bladder cancer	1.49e-05	0.000343	CcSEcCtD
Lamivudine—Diarrhoea—Epirubicin—urinary bladder cancer	1.44e-05	0.000333	CcSEcCtD
Lamivudine—Hypersensitivity—Doxorubicin—urinary bladder cancer	1.44e-05	0.000331	CcSEcCtD
Lamivudine—Vomiting—Methotrexate—urinary bladder cancer	1.43e-05	0.00033	CcSEcCtD
Lamivudine—Rash—Methotrexate—urinary bladder cancer	1.42e-05	0.000327	CcSEcCtD
Lamivudine—Dermatitis—Methotrexate—urinary bladder cancer	1.42e-05	0.000327	CcSEcCtD
Lamivudine—Headache—Methotrexate—urinary bladder cancer	1.41e-05	0.000325	CcSEcCtD
Lamivudine—Asthenia—Doxorubicin—urinary bladder cancer	1.4e-05	0.000323	CcSEcCtD
Lamivudine—Dizziness—Epirubicin—urinary bladder cancer	1.4e-05	0.000321	CcSEcCtD
Lamivudine—Pruritus—Doxorubicin—urinary bladder cancer	1.38e-05	0.000318	CcSEcCtD
Lamivudine—Vomiting—Epirubicin—urinary bladder cancer	1.34e-05	0.000309	CcSEcCtD
Lamivudine—Nausea—Methotrexate—urinary bladder cancer	1.34e-05	0.000309	CcSEcCtD
Lamivudine—Diarrhoea—Doxorubicin—urinary bladder cancer	1.34e-05	0.000308	CcSEcCtD
Lamivudine—Rash—Epirubicin—urinary bladder cancer	1.33e-05	0.000306	CcSEcCtD
Lamivudine—Dermatitis—Epirubicin—urinary bladder cancer	1.33e-05	0.000306	CcSEcCtD
Lamivudine—Headache—Epirubicin—urinary bladder cancer	1.32e-05	0.000304	CcSEcCtD
Lamivudine—Dizziness—Doxorubicin—urinary bladder cancer	1.29e-05	0.000297	CcSEcCtD
Lamivudine—Nausea—Epirubicin—urinary bladder cancer	1.25e-05	0.000289	CcSEcCtD
Lamivudine—Vomiting—Doxorubicin—urinary bladder cancer	1.24e-05	0.000286	CcSEcCtD
Lamivudine—Rash—Doxorubicin—urinary bladder cancer	1.23e-05	0.000284	CcSEcCtD
Lamivudine—Dermatitis—Doxorubicin—urinary bladder cancer	1.23e-05	0.000283	CcSEcCtD
Lamivudine—Headache—Doxorubicin—urinary bladder cancer	1.22e-05	0.000282	CcSEcCtD
Lamivudine—Nausea—Doxorubicin—urinary bladder cancer	1.16e-05	0.000267	CcSEcCtD
Lamivudine—SLC22A1—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	7.93e-06	0.000191	CbGpPWpGaD
Lamivudine—ABCC1—Disease—LIG1—urinary bladder cancer	7.89e-06	0.00019	CbGpPWpGaD
Lamivudine—ABCG2—Metabolism—SLC19A1—urinary bladder cancer	7.87e-06	0.00019	CbGpPWpGaD
Lamivudine—SLC22A2—Metabolism—SLC19A1—urinary bladder cancer	7.79e-06	0.000188	CbGpPWpGaD
Lamivudine—ABCC4—Hemostasis—PLAU—urinary bladder cancer	7.69e-06	0.000185	CbGpPWpGaD
Lamivudine—SLC22A1—Metabolism—CYP4B1—urinary bladder cancer	7.69e-06	0.000185	CbGpPWpGaD
Lamivudine—ABCG2—Metabolism—PRSS3—urinary bladder cancer	7.67e-06	0.000185	CbGpPWpGaD
Lamivudine—PGK1—Metabolism—PTEN—urinary bladder cancer	7.61e-06	0.000184	CbGpPWpGaD
Lamivudine—SLC22A2—Metabolism—PRSS3—urinary bladder cancer	7.59e-06	0.000183	CbGpPWpGaD
Lamivudine—PGK1—Disease—MYC—urinary bladder cancer	7.55e-06	0.000182	CbGpPWpGaD
Lamivudine—SLC22A3—Metabolism—RRM2—urinary bladder cancer	7.55e-06	0.000182	CbGpPWpGaD
Lamivudine—DCK—Metabolism—GSTP1—urinary bladder cancer	7.45e-06	0.00018	CbGpPWpGaD
Lamivudine—NME2—Metabolism—PTGS2—urinary bladder cancer	7.42e-06	0.000179	CbGpPWpGaD
Lamivudine—PGK1—Disease—EGFR—urinary bladder cancer	7.39e-06	0.000178	CbGpPWpGaD
Lamivudine—SLC22A1—Metabolism—SLC19A1—urinary bladder cancer	7.26e-06	0.000175	CbGpPWpGaD
Lamivudine—PGK1—Metabolism—EP300—urinary bladder cancer	7.26e-06	0.000175	CbGpPWpGaD
Lamivudine—NME1—Metabolism—PPARG—urinary bladder cancer	7.15e-06	0.000172	CbGpPWpGaD
Lamivudine—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—urinary bladder cancer	7.14e-06	0.000172	CbGpPWpGaD
Lamivudine—PCYT1A—Metabolism—PTEN—urinary bladder cancer	7.08e-06	0.000171	CbGpPWpGaD
Lamivudine—SLC22A1—Metabolism—PRSS3—urinary bladder cancer	7.07e-06	0.000171	CbGpPWpGaD
Lamivudine—SLC22A3—Metabolism—HPGDS—urinary bladder cancer	6.99e-06	0.000169	CbGpPWpGaD
Lamivudine—SLC22A3—Metabolism—ENO2—urinary bladder cancer	6.99e-06	0.000169	CbGpPWpGaD
Lamivudine—ABCC1—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	6.99e-06	0.000169	CbGpPWpGaD
Lamivudine—PGK1—Disease—KRAS—urinary bladder cancer	6.98e-06	0.000168	CbGpPWpGaD
Lamivudine—ABCC1—Metabolism—TYMP—urinary bladder cancer	6.97e-06	0.000168	CbGpPWpGaD
Lamivudine—ABCC3—Metabolism—RRM2—urinary bladder cancer	6.94e-06	0.000167	CbGpPWpGaD
Lamivudine—DCK—Metabolism—TYMS—urinary bladder cancer	6.92e-06	0.000167	CbGpPWpGaD
Lamivudine—ABCB1—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	6.88e-06	0.000166	CbGpPWpGaD
Lamivudine—NME1—Metabolism—CREBBP—urinary bladder cancer	6.87e-06	0.000166	CbGpPWpGaD
Lamivudine—DCK—Metabolism—NCOR1—urinary bladder cancer	6.84e-06	0.000165	CbGpPWpGaD
Lamivudine—DCK—Metabolism—GSTM1—urinary bladder cancer	6.84e-06	0.000165	CbGpPWpGaD
Lamivudine—SLC22A3—Metabolism—GSTT1—urinary bladder cancer	6.78e-06	0.000164	CbGpPWpGaD
Lamivudine—PCYT1A—Metabolism—EP300—urinary bladder cancer	6.75e-06	0.000163	CbGpPWpGaD
Lamivudine—ABCC1—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	6.69e-06	0.000161	CbGpPWpGaD
Lamivudine—DCK—Metabolism—GPX1—urinary bladder cancer	6.55e-06	0.000158	CbGpPWpGaD
Lamivudine—NME2—Metabolism—PTEN—urinary bladder cancer	6.47e-06	0.000156	CbGpPWpGaD
Lamivudine—DCK—Metabolism—ERCC2—urinary bladder cancer	6.43e-06	0.000155	CbGpPWpGaD
Lamivudine—ABCC3—Metabolism—HPGDS—urinary bladder cancer	6.43e-06	0.000155	CbGpPWpGaD
Lamivudine—ABCC3—Metabolism—ENO2—urinary bladder cancer	6.43e-06	0.000155	CbGpPWpGaD
Lamivudine—ABCC3—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	6.39e-06	0.000154	CbGpPWpGaD
Lamivudine—SLC22A3—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	6.35e-06	0.000153	CbGpPWpGaD
Lamivudine—ABCC4—Hemostasis—CREBBP—urinary bladder cancer	6.34e-06	0.000153	CbGpPWpGaD
Lamivudine—ABCB1—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	6.31e-06	0.000152	CbGpPWpGaD
Lamivudine—ABCC1—Metabolism—NAT2—urinary bladder cancer	6.3e-06	0.000152	CbGpPWpGaD
Lamivudine—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	6.28e-06	0.000151	CbGpPWpGaD
Lamivudine—ABCC4—Hemostasis—IGF1—urinary bladder cancer	6.26e-06	0.000151	CbGpPWpGaD
Lamivudine—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—urinary bladder cancer	6.25e-06	0.000151	CbGpPWpGaD
Lamivudine—ABCC3—Metabolism—GSTT1—urinary bladder cancer	6.23e-06	0.00015	CbGpPWpGaD
Lamivudine—NME2—Metabolism—EP300—urinary bladder cancer	6.17e-06	0.000149	CbGpPWpGaD
Lamivudine—ABCB1—Allograft Rejection—TNF—urinary bladder cancer	6.14e-06	0.000148	CbGpPWpGaD
Lamivudine—ABCC3—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	6.14e-06	0.000148	CbGpPWpGaD
Lamivudine—ABCG2—Metabolism—TYMP—urinary bladder cancer	6.13e-06	0.000148	CbGpPWpGaD
Lamivudine—SLC22A2—Metabolism—TYMP—urinary bladder cancer	6.07e-06	0.000146	CbGpPWpGaD
Lamivudine—DCK—Metabolism—MTHFR—urinary bladder cancer	6.05e-06	0.000146	CbGpPWpGaD
Lamivudine—ABCC1—Disease—ENO2—urinary bladder cancer	6.01e-06	0.000145	CbGpPWpGaD
Lamivudine—PGK1—Disease—HRAS—urinary bladder cancer	5.93e-06	0.000143	CbGpPWpGaD
Lamivudine—ABCC3—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	5.84e-06	0.000141	CbGpPWpGaD
Lamivudine—ABCB1—Metabolism—GSTZ1—urinary bladder cancer	5.77e-06	0.000139	CbGpPWpGaD
Lamivudine—ABCC4—Hemostasis—RHOA—urinary bladder cancer	5.74e-06	0.000138	CbGpPWpGaD
Lamivudine—ABCC1—Disease—RBX1—urinary bladder cancer	5.7e-06	0.000138	CbGpPWpGaD
Lamivudine—SLC22A1—Metabolism—TYMP—urinary bladder cancer	5.65e-06	0.000136	CbGpPWpGaD
Lamivudine—SLC22A3—Metabolism—NQO1—urinary bladder cancer	5.64e-06	0.000136	CbGpPWpGaD
Lamivudine—NME1—Metabolism—PTGS2—urinary bladder cancer	5.62e-06	0.000136	CbGpPWpGaD
Lamivudine—ABCG2—Metabolism—NAT2—urinary bladder cancer	5.54e-06	0.000134	CbGpPWpGaD
Lamivudine—ABCC4—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	5.49e-06	0.000132	CbGpPWpGaD
Lamivudine—SLC22A2—Metabolism—NAT2—urinary bladder cancer	5.49e-06	0.000132	CbGpPWpGaD
Lamivudine—ABCB1—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	5.48e-06	0.000132	CbGpPWpGaD
Lamivudine—ABCB1—Metabolism—NAT1—urinary bladder cancer	5.47e-06	0.000132	CbGpPWpGaD
Lamivudine—ABCB1—Metabolism—GSTO2—urinary bladder cancer	5.47e-06	0.000132	CbGpPWpGaD
Lamivudine—ABCC1—Metabolism—RRM2—urinary bladder cancer	5.44e-06	0.000131	CbGpPWpGaD
Lamivudine—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	5.41e-06	0.000131	CbGpPWpGaD
Lamivudine—ABCC3—Metabolism—NQO1—urinary bladder cancer	5.18e-06	0.000125	CbGpPWpGaD
Lamivudine—SLC22A1—Metabolism—NAT2—urinary bladder cancer	5.11e-06	0.000123	CbGpPWpGaD
Lamivudine—ABCC1—Disease—JAG1—urinary bladder cancer	5.1e-06	0.000123	CbGpPWpGaD
Lamivudine—ABCC1—Metabolism—HPGDS—urinary bladder cancer	5.04e-06	0.000121	CbGpPWpGaD
Lamivudine—ABCC1—Metabolism—ENO2—urinary bladder cancer	5.04e-06	0.000121	CbGpPWpGaD
Lamivudine—ABCC3—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	5.03e-06	0.000121	CbGpPWpGaD
Lamivudine—ABCC1—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	5.01e-06	0.000121	CbGpPWpGaD
Lamivudine—ABCB1—Metabolism—UGT2B7—urinary bladder cancer	5e-06	0.000121	CbGpPWpGaD
Lamivudine—NME1—Metabolism—PTEN—urinary bladder cancer	4.9e-06	0.000118	CbGpPWpGaD
Lamivudine—DCK—Metabolism—PPARG—urinary bladder cancer	4.9e-06	0.000118	CbGpPWpGaD
Lamivudine—ABCC1—Metabolism—GSTT1—urinary bladder cancer	4.89e-06	0.000118	CbGpPWpGaD
Lamivudine—ABCC4—Hemostasis—IL2—urinary bladder cancer	4.81e-06	0.000116	CbGpPWpGaD
Lamivudine—ABCC1—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	4.81e-06	0.000116	CbGpPWpGaD
Lamivudine—ABCG2—Metabolism—RRM2—urinary bladder cancer	4.79e-06	0.000115	CbGpPWpGaD
Lamivudine—SLC22A6—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	4.78e-06	0.000115	CbGpPWpGaD
Lamivudine—SLC22A2—Metabolism—RRM2—urinary bladder cancer	4.74e-06	0.000114	CbGpPWpGaD
Lamivudine—DCK—Metabolism—CREBBP—urinary bladder cancer	4.71e-06	0.000114	CbGpPWpGaD
Lamivudine—SLC22A3—Metabolism—GSTP1—urinary bladder cancer	4.7e-06	0.000113	CbGpPWpGaD
Lamivudine—NME1—Metabolism—EP300—urinary bladder cancer	4.68e-06	0.000113	CbGpPWpGaD
Lamivudine—ABCB1—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	4.65e-06	0.000112	CbGpPWpGaD
Lamivudine—ABCC2—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	4.63e-06	0.000112	CbGpPWpGaD
Lamivudine—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	4.59e-06	0.000111	CbGpPWpGaD
Lamivudine—ABCC1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	4.57e-06	0.00011	CbGpPWpGaD
Lamivudine—SLC22A2—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	4.51e-06	0.000109	CbGpPWpGaD
Lamivudine—ABCB1—Metabolism—CYP4B1—urinary bladder cancer	4.5e-06	0.000109	CbGpPWpGaD
Lamivudine—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	4.49e-06	0.000108	CbGpPWpGaD
Lamivudine—ABCG2—Metabolism—ENO2—urinary bladder cancer	4.43e-06	0.000107	CbGpPWpGaD
Lamivudine—ABCG2—Metabolism—HPGDS—urinary bladder cancer	4.43e-06	0.000107	CbGpPWpGaD
Lamivudine—SLC22A1—Metabolism—RRM2—urinary bladder cancer	4.41e-06	0.000106	CbGpPWpGaD
Lamivudine—SLC22A2—Metabolism—ENO2—urinary bladder cancer	4.39e-06	0.000106	CbGpPWpGaD
Lamivudine—SLC22A2—Metabolism—HPGDS—urinary bladder cancer	4.39e-06	0.000106	CbGpPWpGaD
Lamivudine—ABCC3—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	4.38e-06	0.000106	CbGpPWpGaD
Lamivudine—SLC22A3—Metabolism—TYMS—urinary bladder cancer	4.37e-06	0.000105	CbGpPWpGaD
Lamivudine—ABCC3—Metabolism—GSTP1—urinary bladder cancer	4.32e-06	0.000104	CbGpPWpGaD
Lamivudine—SLC22A3—Metabolism—NCOR1—urinary bladder cancer	4.32e-06	0.000104	CbGpPWpGaD
Lamivudine—SLC22A3—Metabolism—GSTM1—urinary bladder cancer	4.32e-06	0.000104	CbGpPWpGaD
Lamivudine—ABCC4—Hemostasis—EP300—urinary bladder cancer	4.32e-06	0.000104	CbGpPWpGaD
Lamivudine—ABCG2—Metabolism—GSTT1—urinary bladder cancer	4.3e-06	0.000104	CbGpPWpGaD
Lamivudine—ABCB1—Metabolism—SLC19A1—urinary bladder cancer	4.25e-06	0.000103	CbGpPWpGaD
Lamivudine—SLC22A2—Metabolism—GSTT1—urinary bladder cancer	4.25e-06	0.000103	CbGpPWpGaD
Lamivudine—SLC22A1—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	4.2e-06	0.000101	CbGpPWpGaD
Lamivudine—ABCC4—Hemostasis—SRC—urinary bladder cancer	4.2e-06	0.000101	CbGpPWpGaD
Lamivudine—ABCC3—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	4.18e-06	0.000101	CbGpPWpGaD
Lamivudine—ABCB1—Metabolism—PRSS3—urinary bladder cancer	4.15e-06	0.0001	CbGpPWpGaD
Lamivudine—SLC22A3—Metabolism—GPX1—urinary bladder cancer	4.14e-06	9.98e-05	CbGpPWpGaD
Lamivudine—SLC22A1—Metabolism—ENO2—urinary bladder cancer	4.09e-06	9.86e-05	CbGpPWpGaD
Lamivudine—SLC22A1—Metabolism—HPGDS—urinary bladder cancer	4.09e-06	9.86e-05	CbGpPWpGaD
Lamivudine—SLC22A3—Metabolism—ERCC2—urinary bladder cancer	4.06e-06	9.8e-05	CbGpPWpGaD
Lamivudine—ABCC1—Metabolism—NQO1—urinary bladder cancer	4.06e-06	9.79e-05	CbGpPWpGaD
Lamivudine—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	4.05e-06	9.78e-05	CbGpPWpGaD
Lamivudine—ABCG2—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	4.02e-06	9.71e-05	CbGpPWpGaD
Lamivudine—ABCC3—Metabolism—TYMS—urinary bladder cancer	4.02e-06	9.69e-05	CbGpPWpGaD
Lamivudine—SLC22A2—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	3.98e-06	9.61e-05	CbGpPWpGaD
Lamivudine—ABCC3—Metabolism—GSTM1—urinary bladder cancer	3.97e-06	9.58e-05	CbGpPWpGaD
Lamivudine—ABCC3—Metabolism—NCOR1—urinary bladder cancer	3.97e-06	9.58e-05	CbGpPWpGaD
Lamivudine—SLC22A1—Metabolism—GSTT1—urinary bladder cancer	3.97e-06	9.56e-05	CbGpPWpGaD
Lamivudine—ABCC1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	3.94e-06	9.5e-05	CbGpPWpGaD
Lamivudine—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	3.92e-06	9.46e-05	CbGpPWpGaD
Lamivudine—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	3.91e-06	9.44e-05	CbGpPWpGaD
Lamivudine—DCK—Metabolism—PTGS2—urinary bladder cancer	3.86e-06	9.3e-05	CbGpPWpGaD
Lamivudine—SLC22A3—Metabolism—MTHFR—urinary bladder cancer	3.82e-06	9.21e-05	CbGpPWpGaD
Lamivudine—ABCC3—Metabolism—GPX1—urinary bladder cancer	3.8e-06	9.17e-05	CbGpPWpGaD
Lamivudine—ABCC3—Metabolism—ERCC2—urinary bladder cancer	3.73e-06	9.01e-05	CbGpPWpGaD
Lamivudine—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	3.73e-06	9e-05	CbGpPWpGaD
Lamivudine—ABCC1—Disease—NCOR1—urinary bladder cancer	3.72e-06	8.96e-05	CbGpPWpGaD
Lamivudine—SLC22A1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	3.71e-06	8.95e-05	CbGpPWpGaD
Lamivudine—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	3.63e-06	8.75e-05	CbGpPWpGaD
Lamivudine—ABCG2—Metabolism—NQO1—urinary bladder cancer	3.57e-06	8.62e-05	CbGpPWpGaD
Lamivudine—SLC22A2—Metabolism—NQO1—urinary bladder cancer	3.54e-06	8.53e-05	CbGpPWpGaD
Lamivudine—ABCC3—Metabolism—MTHFR—urinary bladder cancer	3.51e-06	8.47e-05	CbGpPWpGaD
Lamivudine—ABCC1—Disease—ERCC2—urinary bladder cancer	3.49e-06	8.43e-05	CbGpPWpGaD
Lamivudine—ABCC4—Hemostasis—KRAS—urinary bladder cancer	3.48e-06	8.39e-05	CbGpPWpGaD
Lamivudine—SLC22A2—Neuronal System—HRAS—urinary bladder cancer	3.45e-06	8.33e-05	CbGpPWpGaD
Lamivudine—ABCC1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	3.44e-06	8.29e-05	CbGpPWpGaD
Lamivudine—ABCC1—Metabolism—GSTP1—urinary bladder cancer	3.39e-06	8.17e-05	CbGpPWpGaD
Lamivudine—DCK—Metabolism—PTEN—urinary bladder cancer	3.36e-06	8.11e-05	CbGpPWpGaD
Lamivudine—ABCB1—Metabolism—TYMP—urinary bladder cancer	3.31e-06	7.99e-05	CbGpPWpGaD
Lamivudine—SLC22A1—Metabolism—NQO1—urinary bladder cancer	3.3e-06	7.95e-05	CbGpPWpGaD
Lamivudine—ABCC1—Disease—MTHFR—urinary bladder cancer	3.28e-06	7.92e-05	CbGpPWpGaD
Lamivudine—ABCC1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	3.28e-06	7.9e-05	CbGpPWpGaD
Lamivudine—ABCC1—Disease—TERT—urinary bladder cancer	3.27e-06	7.9e-05	CbGpPWpGaD
Lamivudine—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	3.25e-06	7.85e-05	CbGpPWpGaD
Lamivudine—SLC22A1—Neuronal System—HRAS—urinary bladder cancer	3.22e-06	7.76e-05	CbGpPWpGaD
Lamivudine—DCK—Metabolism—EP300—urinary bladder cancer	3.21e-06	7.74e-05	CbGpPWpGaD
Lamivudine—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	3.18e-06	7.67e-05	CbGpPWpGaD
Lamivudine—ABCC1—Metabolism—TYMS—urinary bladder cancer	3.15e-06	7.59e-05	CbGpPWpGaD
Lamivudine—ABCC1—Metabolism—GSTM1—urinary bladder cancer	3.11e-06	7.51e-05	CbGpPWpGaD
Lamivudine—ABCC1—Metabolism—NCOR1—urinary bladder cancer	3.11e-06	7.51e-05	CbGpPWpGaD
Lamivudine—SLC22A3—Metabolism—PPARG—urinary bladder cancer	3.1e-06	7.47e-05	CbGpPWpGaD
Lamivudine—ABCC4—Hemostasis—TP53—urinary bladder cancer	3.09e-06	7.45e-05	CbGpPWpGaD
Lamivudine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	3.03e-06	7.31e-05	CbGpPWpGaD
Lamivudine—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	3.01e-06	7.25e-05	CbGpPWpGaD
Lamivudine—ABCC1—Disease—FGFR3—urinary bladder cancer	3.01e-06	7.25e-05	CbGpPWpGaD
Lamivudine—ABCB1—Metabolism—NAT2—urinary bladder cancer	3e-06	7.23e-05	CbGpPWpGaD
Lamivudine—ABCC1—Metabolism—GPX1—urinary bladder cancer	2.98e-06	7.19e-05	CbGpPWpGaD
Lamivudine—ABCG2—Metabolism—GSTP1—urinary bladder cancer	2.98e-06	7.19e-05	CbGpPWpGaD
Lamivudine—SLC22A3—Metabolism—CREBBP—urinary bladder cancer	2.97e-06	7.17e-05	CbGpPWpGaD
Lamivudine—ABCC4—Hemostasis—HRAS—urinary bladder cancer	2.96e-06	7.13e-05	CbGpPWpGaD
Lamivudine—SLC22A2—Metabolism—GSTP1—urinary bladder cancer	2.95e-06	7.11e-05	CbGpPWpGaD
Lamivudine—ABCC1—Metabolism—ERCC2—urinary bladder cancer	2.93e-06	7.06e-05	CbGpPWpGaD
Lamivudine—ABCC3—Metabolism—PPARG—urinary bladder cancer	2.85e-06	6.86e-05	CbGpPWpGaD
Lamivudine—ABCG2—Metabolism—TYMS—urinary bladder cancer	2.77e-06	6.68e-05	CbGpPWpGaD
Lamivudine—ABCC1—Metabolism—MTHFR—urinary bladder cancer	2.75e-06	6.63e-05	CbGpPWpGaD
Lamivudine—SLC22A1—Metabolism—GSTP1—urinary bladder cancer	2.75e-06	6.63e-05	CbGpPWpGaD
Lamivudine—SLC22A2—Metabolism—TYMS—urinary bladder cancer	2.74e-06	6.61e-05	CbGpPWpGaD
Lamivudine—ABCG2—Metabolism—NCOR1—urinary bladder cancer	2.74e-06	6.6e-05	CbGpPWpGaD
Lamivudine—ABCG2—Metabolism—GSTM1—urinary bladder cancer	2.74e-06	6.6e-05	CbGpPWpGaD
Lamivudine—ABCC3—Metabolism—CREBBP—urinary bladder cancer	2.73e-06	6.59e-05	CbGpPWpGaD
Lamivudine—SLC22A2—Metabolism—GSTM1—urinary bladder cancer	2.71e-06	6.54e-05	CbGpPWpGaD
Lamivudine—SLC22A2—Metabolism—NCOR1—urinary bladder cancer	2.71e-06	6.54e-05	CbGpPWpGaD
Lamivudine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	2.67e-06	6.44e-05	CbGpPWpGaD
Lamivudine—ABCG2—Metabolism—GPX1—urinary bladder cancer	2.62e-06	6.32e-05	CbGpPWpGaD
Lamivudine—SLC22A2—Metabolism—GPX1—urinary bladder cancer	2.6e-06	6.26e-05	CbGpPWpGaD
Lamivudine—ABCB1—Metabolism—RRM2—urinary bladder cancer	2.59e-06	6.24e-05	CbGpPWpGaD
Lamivudine—ABCG2—Metabolism—ERCC2—urinary bladder cancer	2.57e-06	6.21e-05	CbGpPWpGaD
Lamivudine—ABCC1—Disease—CREBBP—urinary bladder cancer	2.56e-06	6.17e-05	CbGpPWpGaD
Lamivudine—SLC22A1—Metabolism—TYMS—urinary bladder cancer	2.56e-06	6.16e-05	CbGpPWpGaD
Lamivudine—SLC22A2—Metabolism—ERCC2—urinary bladder cancer	2.55e-06	6.15e-05	CbGpPWpGaD
Lamivudine—SLC22A1—Metabolism—NCOR1—urinary bladder cancer	2.53e-06	6.09e-05	CbGpPWpGaD
Lamivudine—SLC22A1—Metabolism—GSTM1—urinary bladder cancer	2.53e-06	6.09e-05	CbGpPWpGaD
Lamivudine—SLC22A3—Metabolism—PTGS2—urinary bladder cancer	2.44e-06	5.88e-05	CbGpPWpGaD
Lamivudine—ABCG2—Metabolism—MTHFR—urinary bladder cancer	2.42e-06	5.84e-05	CbGpPWpGaD
Lamivudine—SLC22A1—Metabolism—GPX1—urinary bladder cancer	2.42e-06	5.83e-05	CbGpPWpGaD
Lamivudine—ABCB1—Metabolism—HPGDS—urinary bladder cancer	2.4e-06	5.78e-05	CbGpPWpGaD
Lamivudine—ABCB1—Metabolism—ENO2—urinary bladder cancer	2.4e-06	5.78e-05	CbGpPWpGaD
Lamivudine—SLC22A2—Metabolism—MTHFR—urinary bladder cancer	2.39e-06	5.78e-05	CbGpPWpGaD
Lamivudine—SLC22A1—Metabolism—ERCC2—urinary bladder cancer	2.37e-06	5.73e-05	CbGpPWpGaD
Lamivudine—ABCB1—Metabolism—GSTT1—urinary bladder cancer	2.32e-06	5.61e-05	CbGpPWpGaD
Lamivudine—ABCC1—Disease—RHOA—urinary bladder cancer	2.31e-06	5.58e-05	CbGpPWpGaD
Lamivudine—ABCC3—Metabolism—PTGS2—urinary bladder cancer	2.24e-06	5.4e-05	CbGpPWpGaD
Lamivudine—SLC22A1—Metabolism—MTHFR—urinary bladder cancer	2.23e-06	5.38e-05	CbGpPWpGaD
Lamivudine—ABCC1—Metabolism—PPARG—urinary bladder cancer	2.23e-06	5.38e-05	CbGpPWpGaD
Lamivudine—ABCB1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	2.18e-06	5.25e-05	CbGpPWpGaD
Lamivudine—ABCC1—Metabolism—CREBBP—urinary bladder cancer	2.14e-06	5.17e-05	CbGpPWpGaD
Lamivudine—ABCC1—Disease—ERBB2—urinary bladder cancer	2.14e-06	5.17e-05	CbGpPWpGaD
Lamivudine—SLC22A3—Metabolism—PTEN—urinary bladder cancer	2.12e-06	5.12e-05	CbGpPWpGaD
Lamivudine—ABCC1—Disease—PTGS2—urinary bladder cancer	2.09e-06	5.05e-05	CbGpPWpGaD
Lamivudine—SLC22A3—Metabolism—EP300—urinary bladder cancer	2.03e-06	4.89e-05	CbGpPWpGaD
Lamivudine—ABCG2—Metabolism—PPARG—urinary bladder cancer	1.96e-06	4.73e-05	CbGpPWpGaD
Lamivudine—ABCC3—Metabolism—PTEN—urinary bladder cancer	1.95e-06	4.71e-05	CbGpPWpGaD
Lamivudine—SLC22A2—Metabolism—PPARG—urinary bladder cancer	1.94e-06	4.68e-05	CbGpPWpGaD
Lamivudine—ABCB1—Metabolism—NQO1—urinary bladder cancer	1.93e-06	4.66e-05	CbGpPWpGaD
Lamivudine—ABCG2—Metabolism—CREBBP—urinary bladder cancer	1.89e-06	4.55e-05	CbGpPWpGaD
Lamivudine—SLC22A2—Metabolism—CREBBP—urinary bladder cancer	1.87e-06	4.5e-05	CbGpPWpGaD
Lamivudine—ABCC3—Metabolism—EP300—urinary bladder cancer	1.86e-06	4.49e-05	CbGpPWpGaD
Lamivudine—ABCC1—Disease—CDKN1A—urinary bladder cancer	1.83e-06	4.42e-05	CbGpPWpGaD
Lamivudine—ABCC1—Disease—PTEN—urinary bladder cancer	1.83e-06	4.41e-05	CbGpPWpGaD
Lamivudine—SLC22A1—Metabolism—PPARG—urinary bladder cancer	1.81e-06	4.37e-05	CbGpPWpGaD
Lamivudine—ABCC1—Metabolism—PTGS2—urinary bladder cancer	1.75e-06	4.23e-05	CbGpPWpGaD
Lamivudine—ABCC1—Disease—EP300—urinary bladder cancer	1.74e-06	4.2e-05	CbGpPWpGaD
Lamivudine—SLC22A1—Metabolism—CREBBP—urinary bladder cancer	1.74e-06	4.19e-05	CbGpPWpGaD
Lamivudine—ABCC1—Disease—SRC—urinary bladder cancer	1.69e-06	4.09e-05	CbGpPWpGaD
Lamivudine—ABCB1—Metabolism—GSTP1—urinary bladder cancer	1.61e-06	3.89e-05	CbGpPWpGaD
Lamivudine—ABCG2—Metabolism—PTGS2—urinary bladder cancer	1.54e-06	3.72e-05	CbGpPWpGaD
Lamivudine—ABCC1—Metabolism—PTEN—urinary bladder cancer	1.53e-06	3.69e-05	CbGpPWpGaD
Lamivudine—SLC22A2—Metabolism—PTGS2—urinary bladder cancer	1.53e-06	3.68e-05	CbGpPWpGaD
Lamivudine—ABCC1—Disease—MYC—urinary bladder cancer	1.52e-06	3.66e-05	CbGpPWpGaD
Lamivudine—ABCB1—Metabolism—TYMS—urinary bladder cancer	1.5e-06	3.61e-05	CbGpPWpGaD
Lamivudine—ABCC1—Disease—EGFR—urinary bladder cancer	1.48e-06	3.58e-05	CbGpPWpGaD
Lamivudine—ABCB1—Metabolism—NCOR1—urinary bladder cancer	1.48e-06	3.57e-05	CbGpPWpGaD
Lamivudine—ABCB1—Metabolism—GSTM1—urinary bladder cancer	1.48e-06	3.57e-05	CbGpPWpGaD
Lamivudine—ABCC1—Metabolism—EP300—urinary bladder cancer	1.46e-06	3.52e-05	CbGpPWpGaD
Lamivudine—SLC22A1—Metabolism—PTGS2—urinary bladder cancer	1.42e-06	3.43e-05	CbGpPWpGaD
Lamivudine—ABCB1—Metabolism—GPX1—urinary bladder cancer	1.42e-06	3.42e-05	CbGpPWpGaD
Lamivudine—ABCC1—Disease—KRAS—urinary bladder cancer	1.4e-06	3.38e-05	CbGpPWpGaD
Lamivudine—ABCB1—Metabolism—ERCC2—urinary bladder cancer	1.39e-06	3.36e-05	CbGpPWpGaD
Lamivudine—ABCG2—Metabolism—PTEN—urinary bladder cancer	1.35e-06	3.25e-05	CbGpPWpGaD
Lamivudine—SLC22A2—Metabolism—PTEN—urinary bladder cancer	1.33e-06	3.21e-05	CbGpPWpGaD
Lamivudine—ABCB1—Metabolism—MTHFR—urinary bladder cancer	1.31e-06	3.16e-05	CbGpPWpGaD
Lamivudine—ABCG2—Metabolism—EP300—urinary bladder cancer	1.28e-06	3.1e-05	CbGpPWpGaD
Lamivudine—SLC22A2—Metabolism—EP300—urinary bladder cancer	1.27e-06	3.06e-05	CbGpPWpGaD
Lamivudine—SLC22A1—Metabolism—PTEN—urinary bladder cancer	1.24e-06	3e-05	CbGpPWpGaD
Lamivudine—ABCC1—Disease—HRAS—urinary bladder cancer	1.19e-06	2.88e-05	CbGpPWpGaD
Lamivudine—SLC22A1—Metabolism—EP300—urinary bladder cancer	1.18e-06	2.86e-05	CbGpPWpGaD
Lamivudine—ABCB1—Metabolism—PPARG—urinary bladder cancer	1.06e-06	2.56e-05	CbGpPWpGaD
Lamivudine—ABCB1—Metabolism—CREBBP—urinary bladder cancer	1.02e-06	2.46e-05	CbGpPWpGaD
Lamivudine—ABCB1—Metabolism—PTGS2—urinary bladder cancer	8.35e-07	2.01e-05	CbGpPWpGaD
Lamivudine—ABCB1—Metabolism—PTEN—urinary bladder cancer	7.28e-07	1.76e-05	CbGpPWpGaD
Lamivudine—ABCB1—Metabolism—EP300—urinary bladder cancer	6.94e-07	1.67e-05	CbGpPWpGaD
